NCT02596074View on ClinicalTrials.gov

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 7, 2017

Study Completion Date

July 4, 2017

Conditions
Usual Type Vulval Intraepithelial Neoplasia (uVIN)
Interventions
DRUG

Omiganan (CLS001) topical gel

DRUG

Vehicle topical gel

Trial Locations (1)

Unknown

LUMC/Centre for Human Drug Research, Leiden

All Listed Sponsors
lead

Maruho Co., Ltd.

INDUSTRY

NCT02596074 - Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN | Biotech Hunter | Biotech Hunter